Search research articles
Contact Us
Filters
Showing results (321-330 of 344) with videos related to
Page
of 35
Sort By:
Bone
|
November 7, 2021
Whole exome sequencing reveals potentially pathogenic variants in a small subset of premenopausal women with idiopathic osteoporosis
Adi Cohen, Joseph Hostyk, Evan H Baugh, et al.
Tuberculosis (Edinburgh, Scotland)
|
October 29, 2005
Bovine tuberculosis in India: potential basis for zoonosis
H K Prasad, A Singhal, A Mishra, et al.
Clinical Genetics
|
July 3, 2013
Coffin-Siris syndrome is a SWI/SNF complex disorder
Y Tsurusaki, N Okamoto, H Ohashi, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 28, 2016
The Role of Stereotactic Radiosurgery in the Reirradiation of Metastatic Spinal Tumors
C K Ho, K A Kumar, E C White, et al.
Kidney International Reports
|
October 11, 2022
Clinical Real-Time Genome Sequencing to Solve the Complex and Confounded Presentation of a Child With Focal Segmental Glomerulosclerosis and Multiple Malignancies
Namrata G Jain, Dina F Ahram, Maddalena Marasa, et al.
Annals of the New York Academy of Sciences
|
July 23, 1999
Novel bioartificial liver support system: preclinical evaluation
J F Patzer, G V Mazariegos, R Lopez, et al.
Blood Cancer Journal
|
April 22, 2017
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment
M A Dimopoulos, A K Stewart, T Masszi, et al.
Leukemia
|
December 28, 2016
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
W-J Chng, H Goldschmidt, M A Dimopoulos, et al.
Leukemia
|
August 6, 2016
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
P Moreau, D Joshua, W-J Chng, et al.
Clinical Genetics
|
May 6, 2016
Identification and characterization of 20 novel pathogenic variants in 60 unrelated Indian patients with mucopolysaccharidoses type I and type II
A Uttarilli, P Ranganath, D Matta, et al.
Page
of 35
Search research articles
Search
Showing results (321-330 of 344) with videos related to
Sort By:
Page
of 35
Bone
|
November 7, 2021
Whole exome sequencing reveals potentially pathogenic variants in a small subset of premenopausal women with idiopathic osteoporosis
Adi Cohen, Joseph Hostyk, Evan H Baugh, et al.
Tuberculosis (Edinburgh, Scotland)
|
October 29, 2005
Bovine tuberculosis in India: potential basis for zoonosis
H K Prasad, A Singhal, A Mishra, et al.
Clinical Genetics
|
July 3, 2013
Coffin-Siris syndrome is a SWI/SNF complex disorder
Y Tsurusaki, N Okamoto, H Ohashi, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 28, 2016
The Role of Stereotactic Radiosurgery in the Reirradiation of Metastatic Spinal Tumors
C K Ho, K A Kumar, E C White, et al.
Kidney International Reports
|
October 11, 2022
Clinical Real-Time Genome Sequencing to Solve the Complex and Confounded Presentation of a Child With Focal Segmental Glomerulosclerosis and Multiple Malignancies
Namrata G Jain, Dina F Ahram, Maddalena Marasa, et al.
Annals of the New York Academy of Sciences
|
July 23, 1999
Novel bioartificial liver support system: preclinical evaluation
J F Patzer, G V Mazariegos, R Lopez, et al.
Blood Cancer Journal
|
April 22, 2017
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment
M A Dimopoulos, A K Stewart, T Masszi, et al.
Leukemia
|
December 28, 2016
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
W-J Chng, H Goldschmidt, M A Dimopoulos, et al.
Leukemia
|
August 6, 2016
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
P Moreau, D Joshua, W-J Chng, et al.
Clinical Genetics
|
May 6, 2016
Identification and characterization of 20 novel pathogenic variants in 60 unrelated Indian patients with mucopolysaccharidoses type I and type II
A Uttarilli, P Ranganath, D Matta, et al.
Page
of 35